

EXPRESS MAIL LABEL  
ATTORNEY'S CHECKET NUMBER  
C-1510 USA

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

3 (filed)  
NSMITTAL LETTER TO THE UNITED STATES  
DESIGNATED/ELECTED OFFICE (DO/EO/US)  
CONCERNING A FILING UNDER 35 U.S.C. 371

ORIGINAL APPLICATION NO.  
PCT/US00/13651  
INTERNATIONAL FILING DATE  
17 May 2000 (17.05.00)

U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR 1.52)  
09/623533  
PRIORITY DATE CLAIMED  
17 May 1999 (17.05.99)

05 SEP 2000

INVENTION  
FASTING FUSION PEPTIDE INHIBITORS OF VIRAL INFECTION  
526 Rec'd PCT

APPLICANT(S) FOR DO/EO/US  
BRIDON, Dominique P.; DUFRESNE, Robert S.; BOUDJELLAB, Nissab; ROBITAILLE, Martin; MILNER, Peter G.

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

- 1 ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
- 2 ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
- 3 ☒ This is an express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).
- 4 ☐ A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.
- 5 ☒ A copy of the International Application as filed (35 U.S.C. 371 (c) (2))
  - a ☒ is transmitted herewith (required only if not transmitted by the International Bureau). (Request, Description, Claims, Abstract, Tables, Sequence Listing)
  - b ☐ has been transmitted by the International Bureau.
  - c ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
- 6 ☐ A translation of the International Search Report (PCT/ISA/210).
- 7 ☐ A copy of the International Search Report (PCT/ISA/210).
- 8 ☒ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3))
  - a ☐ are transmitted herewith (required only if not transmitted by the International Bureau).
  - b ☐ have been transmitted by the International Bureau.
  - c ☒ have not been made; however, the time limit for making such amendments has NOT expired.
  - d ☐ have not been made and will not be made.
- 9 ☐ A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371 (c)(3)).
- 10 ☒ An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)). (signed)
- 11 ☐ A copy of the International Preliminary Examination Report (PCT/IPEA/409).
- 12 ☐ A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371 (c)(5)).

Items 13 to 20 below concern document(s) or information included:

- 13 ☐ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
- 14 ☒ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
- 15 ☐ An assignment amendment.
- 16 ☐ A **FIRST** preliminary amendment.
- 17 ☐ A **SECOND** or **SUBSEQUENT** preliminary amendment.
- 18 ☐ A substitute specification.
- 19 ☐ A change of power of attorney and/or address letter.
- 20 ☒ Certificate of Mailing by Express Mail
- 21 ☒ Other items or information:
  - a. Copy of Sequence Listing in computer readable form as originally filed 17 May 2000 (17.05.00).
  - b. Copy of Form PCT/IB/301 - Notification of Receipt of Record Copy.
  - c. Two copies of Form PCT/IB/304 - Notification Concerning Submission or Transmittal of Priority Document.
  - d. Verified Statement (Declaration) Claiming Small Entity Status - Small Business Concern (signed).

21. The following fees are submitted:

**BASIC NATIONAL FEE ( 37 CFR 1.492 (a) (1) - (5)) :**

- ☐ Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO ..... \$970.00
- ☒ International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO ..... \$840.00
- ☐ International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO ..... \$690.00
- ☐ International preliminary examination fee paid to USPTO (37 CFR 1.482) but all claims did not satisfy provisions of PCT Article 33(1)-(4) ..... \$670.00
- ☐ International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(1)-(4) ..... \$96.00

**ENTER APPROPRIATE BASIC FEE AMOUNT =**

Surcharge of \$130.00 for furnishing the oath or declaration later than months from the earliest claimed priority date (37 CFR 1.492 (e)). ☐ 20 ☐ 30

CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE
Total claims	30 - 20 =	10	x \$18.00
Independent claims	5 - 3 =	2	x \$78.00

Multiple Dependent Claims (check if applicable). ☐**TOTAL OF ABOVE CALCULATIONS =**

Reduction of 1/2 for filing by small entity, if applicable. Verified Small Entity Statement must also be filed (Note 37 CFR 1.9, 1.27, 1.28) (check if applicable). ☒

**SUBTOTAL =**

Processing fee of \$130.00 for furnishing the English translation later than months from the earliest claimed priority date (37 CFR 1.492 (f)). ☐ 20 ☐ 30

**TOTAL NATIONAL FEE =**

Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31) (check if applicable). ☒

**TOTAL FEES ENCLOSED =**

Amount to be:  
refunded \$  
charged \$

- ☐ A check in the amount of \$628.00 to cover the above fees is enclosed.
- ☐ Please charge my Deposit Account No. in the amount of to cover the above fees.  
A duplicate copy of this sheet is enclosed.
- ☒ The Commissioner is hereby authorized to charge any fees which may be required, or credit any overpayment to Deposit Account No. 12-1420 A duplicate copy of this sheet is enclosed.

**NOTE:** Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

Michael R. Ward, Esq.  
LIMBACH & LIMBACH L.L.P.  
2001 Ferry Building  
San Francisco, California 94111-4207  
United States of America  
Telephone: (415) 433-4150  
Facsimile: (415) 433-8716

*Michael R. Ward*

SIGNATURE

MICHAEL R. WARD

NAME

38,651

REGISTRATION NUMBER

05 September 2000 (05.09.00)

DATE

526 Rec'd

05 SEP 2000

097623533

533 Rec'd PCT/PTO 05 SEP 2000

PATENT

PATENT COOPERATION TREATY  
UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US)

In re Nat'l Phase Application of: )  
 )  
DOMINIQUE P. BRIDON ET AL. )  
 )  
Based Upon International ) CERTIFICATION  
Application No. PCT/US00/13651 ) UNDER  
Int'l Filing Date: 17 May 2000 ) 37 CFR §1.10  
 )  
Serial No.: Not Assigned )  
 )  
A Filing Under 35 U.S.C. 371 on: )  
05 September 2000 (05.09.00) )  
 )  
For: **LONG LASTING FUSION PEPTIDE** )  
**INHIBITORS OF VIRAL INFECTION** )  
 )  
 )  
 )

Assistant Commissioner for Patents  
Box PCT  
Washington, D.C. 20231-0001

Attention: U.S. Designated/Elected Office (DO/EO/US)

Dear Sir:

I hereby certify that this Application for entering the national phase of the above-identified International Application and the documents referred to as enclosed herein are being deposited with the United States Postal Service on this date, **05 September 2000 (05.09.00)**, in an envelope bearing "Express Mail Post Office to Addressee" Mailing Label Number **EL387347602US** addressed to: Assistant Commissioner for Patents, Box PCT, Washington, D.C. 20231-0001, Attention U.S. Designated/Elected Office (DO/EO/US).

Enclosed are:

1. Transmittal Letter to the U.S. Designated/Elected Office (DO/EO/US) Concerning A Filing Under 35 U.S.C. 371, in duplicate;
2. Request, description, claims, abstract, tables, and sequence listing of International Application No. PCT/US00/13651 as originally filed 17 May 2000 (17.05.00);

005060" E252960

3. Copy of Sequence Listing in computer readable form as originally filed 17 May 2000 (17.05.00);
4. Form PCT/IB/301 -- Notification of Receipt of Record Copy;
5. Form PCT/IB/304 -- Notification Concerning Submission or Transmittal of Priority Document (two forms);
6. Combined Declaration/Power of Attorney/Claim of Priority (**signed**);
7. Assignment (**signed**) with Form PTO-1595 (Assignment Recordation Form);
8. Verified Statement (Declaration) Claiming Small Entity Status -- Small Business Concern (**signed**);
9. Check in the amount of \$628.00; and
10. Acknowledgement Postcard.

Dated: 05 September 2000 (05.09.00)

*Elizabeth A. Reicker*  
Elizabeth A. Reicker

LIMBACH & LIMBACH L.L.P.  
2001 Ferry Building  
San Francisco, California 94111  
Telephone: (415) 433-4150  
Facsimile: (415) 433-8716

Attorney Docket No. REDC-1510 USA

005060 "EE3E2960

Applicant or Patentee: DOMINIQUE P. BRIDON ET AL.

Appn. or Patent No.:

Filed or Issued: HEREWITHFor: LONG LASTING FUSION PEPTIDE INHIBITORS OF VIRAL INFECTIONAttorney's  
Docket No.: REDC-1510 USA**VERIFIED STATEMENT (DECLARATION) CLAIMING SMALL ENTITY  
STATUS (37 CFR 1.9(f) and 1.27(c)) - SMALL BUSINESS CONCERN**

I hereby declare that I am

- ☐ the owner of the small business concern identified below:  
☒ an official of the small business concern empowered to act on behalf of the concern identified below:

NAME OF CONCERN CONJUCHEM, INC.ADDRESS OF CONCERN 225 President Kennedy Avenue West, Third Floor, Suite 3950, Montreal, Quebec H2X 3Y8,  
Canada

I hereby declare that the above identified small business concern qualifies as a small business concern as defined in 13 CFR 121.3-18, and reproduced in 37 CFR 1.9(d), for purposes of paying reduced fees under section 41(a) and (b) of Title 35, United States Code, in that the number of employees of the concern, including those of its affiliates, does not exceed 500 persons. For purposes of this statement, (1) the number of employees of the business concern is the average over the previous fiscal year of the concern of the persons employed on a full-time, part-time or temporary basis during each of the pay periods of the fiscal year, and (2) concerns are affiliates of each other when either, directly or indirectly, one concern controls or has the power to control the other, or a third party or parties controls or has the power to control both.

I hereby declare that rights under contract or law have been conveyed to and remain with the small business concern identified above with regard to the invention, entitled LONG LASTING FUSION PEPTIDE INHIBITORS OF VIRAL INFECTION by inventor(s) DOMINIQUE P. BRIDON ET AL. described in

- ☒ the specification filed herewith with title as listed above.  
☐ application no. \_\_\_\_\_, filed \_\_\_\_\_  
☐ patent no. \_\_\_\_\_, issued \_\_\_\_\_

If the rights held by the above identified small business concern are not exclusive, each individual, concern or organization having rights to the invention is listed below\* and no rights to the invention are held by any person, other than the inventor, who could not qualify as an independent inventor under 37 CFR 1.9(c) if that person made the invention, or by any concern which would not qualify as a small business concern under 37 CFR 1.9(d) or a nonprofit organization under 37 CFR 1.9(e).

\*NOTE: Separate verified statements are required from each named person, concern or organization having rights to the invention averring to their status as small entities. (37 CFR 1.27).

NAME \_\_\_\_\_

ADDRESS \_\_\_\_\_

☐ Individual ☐ Small Business Concern ☐ Nonprofit Organization

NAME \_\_\_\_\_

ADDRESS \_\_\_\_\_

☐ Individual ☐ Small Business Concern ☐ Nonprofit Organization

I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time or paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate. (37 CFR 1.28(b))

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application, any patent issuing thereon, or any patent to which this verified statement is directed.

NAME OF PERSON SIGNING Dominique P. BridonTITLE OF PERSON OTHER THAN OWNER Vice President of ResearchADDRESS OF PERSON SIGNING 225 President Kennedy Avenue West, Third Floor, Suite 3950, Montreal, Quebec H2X 3Y8, CanadaSIGNATURE: DATE: Aug 15, 2000